Adalimumab for the treatment of uveitis

Kara C. LaMattina, Debra A. Goldstein*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Introduction: Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis. Areas covered: The aim of this review is to summarize the research which demonstrated the effectiveness of adalimumab in the treatment of intraocular inflammation and helped to establish its side effect profile, ultimately leading to its FDA approval. Expert commentary: Adalimumab is a useful second-line agent in the treatment of non-infectious uveitis. While it is only approved in the United States for use in intermediate, posterior, and panuveitis in adults, I find it to be effective in off-label treatment of pediatric uveitis and scleritis as well.

Original languageEnglish (US)
Pages (from-to)181-188
Number of pages8
JournalExpert Review of Clinical Immunology
Issue number3
StatePublished - Mar 4 2017


  • Adalimumab
  • Behçet
  • TNF
  • ankylosing spondylitis
  • biologic
  • juvenile idiopathic arthritis
  • sarcoidosis
  • tumor necrosis factor-alpha
  • uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Adalimumab for the treatment of uveitis'. Together they form a unique fingerprint.

Cite this